...
首页> 外文期刊>Biological chemistry >Pharmacological and genetic evidence that cathepsin B is not the physiological activator of rodent prorenin.
【24h】

Pharmacological and genetic evidence that cathepsin B is not the physiological activator of rodent prorenin.

机译:药理和遗传学证据表明组织蛋白酶B不是啮齿动物原肾素的生理激活剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Renin is the first enzyme in the renin-angiotensin-aldosterone system which is the principal regulator of blood pressure and hydroelectrolyte balance. Previous studies suggest that cathepsin B is the activator of the prorenin zymogen. Here, we show no difference in plasma renin activity, or mean arterial blood pressure between wild-type and cathepsin B knockout mice. To account for potential gene compensation, a potent, selective, reversible cathepsin B inhibitor was developed to determine the role of cathepsin B on prorenin processing in rats. Pharmacological inhibition of cathepsin B in spontaneously hypertensive and double transgenic rats did not result in a reduction in renal mature renin protein levels or plasma renin activity. We conclude that cathepsin B does not play a significant role in this process in rodents.
机译:肾素是肾素-血管紧张素-醛固酮系统中的第一种酶,它是血压和水电解质平衡的主要调节剂。先前的研究表明,组织蛋白酶B是促肾上腺素原酶原的激活剂。在这里,我们没有显示血浆肾素活性或野生型和组织蛋白酶B基因敲除小鼠之间的平均动脉血压的差异。为了说明潜在的基因补偿,开发了一种有效的,选择性的,可逆的组织蛋白酶B抑制剂,以确定组织蛋白酶B在大鼠中肾素原处理中的作用。自发性高血压和双重转基因大鼠中组织蛋白酶B的药理抑制作用不会导致肾成熟肾素蛋白水平或血浆肾素活性降低。我们得出结论,组织蛋白酶B在啮齿类动物的这一过程中没有发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号